Blog
RSS FeedPosted by Michael Wonder on 20 Jun 2019
Innovative treatment for inflammatory eye condition recommended for use on the NHS
20 June 2019 - People with recurrent non-infectious uveitis affecting the back of the eye could benefit from a new treatment ...
Posted by Michael Wonder on 19 Jun 2019
NICE nod for Blincyto
19 June 2019 - NICE has announced the recommendation of Amgen’s Blincyto (blinatumomab) for treating acute lymphoblastic leukaemia. ...
Posted by Michael Wonder on 30 May 2019
NICE backs Merck's Prevymis for CMV
30 May 2019 - NICE has published its final appraisal document for the use of Merck's Prevymis (letermovir/ID1153) in preventing ...
Posted by Michael Wonder on 24 May 2019
Final NICE guidance issued for Akcea’s Tegsedi
24 May 2019 - Akcea Therapeutics UK has announced that NICE has published a final guideline for its nerve damage ...
Posted by Michael Wonder on 18 May 2019
NICE recommends Revlimid as multiple myeloma alternative
17 May 2019 - NICE has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight ...
Posted by Michael Wonder on 15 May 2019
NICE recommends first ever treatment for children with rare muscle wasting condition
15 May 2019 - Children with the rare genetic disorder spinal muscular atrophy can now be treated with nusinersen after NICE ...
Posted by Michael Wonder on 09 May 2019
Lower price for MS drug paves the way for positive recommendation from NICE
9 May 2019 - A new, lower price for a drug to treat a rarer form of multiple sclerosis in adults ...
Posted by Michael Wonder on 09 May 2019
Hope for multiple sclerosis sufferers after green light for drug which can delay wheelchair use by seven years
9 May 2019 - Multiple sclerosis patients have welcomed an NHS decision to fund a “landmark” drug which can delay ...
Posted by Michael Wonder on 03 May 2019
NICE recommends Roche’s Tecentriq for metastatic NSCLC
3 May 2019 - NICE has published final draft guidance recommending Roche’s Tecentriq in combination with other therapies for metastatic ...
Posted by Michael Wonder on 21 Apr 2019
NICE publishes final recommendation for Almirall's Ilumetri (tildrakizumab), as a cost-effective option for adults with moderate-to-severe plaque psoriasis
17 April 2019 - Tildrakizumab was approved by the European Commission in September 2018, is already available in Germany and is ...
Posted by Michael Wonder on 20 Apr 2019
NICE final guidance published for Cimzia
18 April 2019 - NICE has shared its final guidance for the recommended use of UCB’s Cimzia (certolizumab pegol). ...
Posted by Michael Wonder on 16 Apr 2019
Akcea steals march on Alnylam with NICE approval
16 April 2019 - Advantage to Tegsedi over Onpattro. ...
Posted by Michael Wonder on 10 Apr 2019
Novartis’ Kisqali hit with NICE rejection
10 April 2019 - NICE has issued a draft guidance which does not recommend Novartis’ Kisqali (ribociclib), which is typically ...
Posted by Michael Wonder on 07 Apr 2019
NICE appraisal for BMS kidney cancer immunotherapy combination
5 April 2019 - NICE has issued a Final Appraisal Determination endorsing NHS use of an Opdivo (nivolumab) and Yervoy ...
Posted by Michael Wonder on 02 Apr 2019
NICE nod for breast cancer delay drug
2 April 2019 - NICE has recommended Eli Lilly’s Verzenio (abemaciclib) when given with Faslodex (fulvestrant), to be available for ...